Tag: #Global Trends

On January 8, 2026, the multinational biopharmaceutical giant AstraZeneca officially announced the appointment of a new Head of Investor Relations.... Read more

On January 12, 2026, the European Commission officially approved Sanofi’s Teizeild (teplizumab). This marks the first disease-modifying therapy authorized in... Read more

January 2026 has marked a vibrant start for the biomedical venture capital market with the launch of three new funds,... Read more

Alveus Therapeutics has made its debut following a successful $160 million Series A financing round. Led by prominent healthcare investors... Read more

Swiss drugmaker Novartis has unveiled plans to construct a new radioligand therapy (RLT) manufacturing plant in Winter Park, Florida. This... Read more

Johnson & Johnson (J&J) has officially joined the ranks of biopharma giants striking "Most-Favored-Nation" (MFN) drug pricing agreements with the... Read more

Tessera Therapeutics, a genetic medicine firm backed by Flagship Pioneering, has disclosed plans to lay off 90 employees across several... Read more

Ollin Biosciences has reported compelling data from its Phase 1b "Jade" study, highlighting the superior performance of its bispecific antibody,... Read more

Pharmaceutical giant GSK has announced successful outcomes from its Phase III B-Well 1 and B-Well 2 clinical trials, establishing a... Read more